São Paulo, 4th July 2018: SOPHiA GENETICS, global leader in Data-Driven Medicine, today announced that the company has welcomed three new leading healthcare institutions, ten in total, from across the country who have adopted SOPHiA AI, the universal technology for clinical genomics analysis.
SOPHiA GENETICS is making a meaningful contribution, supporting and accelerating the adoption of clinical genomic testing in Brazil. The company’s solutions are answering healthcare institutions’ Data-Driven Medicine needs for a direct benefit to patients.
Brazilian institutions use the company’s AI technology to detect and characterize all type of disease-causing genomic alterations. This valuable information helps them better and faster diagnose their patients suffering from hereditary diseases and cancers.
As explained by Dra. Dirce Carraro, Head of the Genomics and Molecular Biology Laboratory at AC Camargo Cancer Center: “The Hereditary Cancer Solution by SOPHiA GENETICS has shown excellent reproducible results for the detection of very complex to find alterations such as SNVs, Indels and CNVs giving us the possibility to streamline the analysis quickly into our routine testing”
GeneOne is a genomics laboratory that is part of the DASA group, Latin America’s largest diagnostic medicine company. Gustavo Campana, Medical Director of Clinical Analysis at DASA revealed the following:“After working with SOPHiA’s analytical technology for more than 2 years, moving towards a customized application was a natural choice for us. We truly believe SOPHiA GENETICS will become a long-lasting partner in the growth and establishment of GeneOne at the forefront of genomic testing in Brazil and Latin America”
Hospital de Amor, previously known as the Hospital de Cancer de Barretos, is a philanthropic hospital specialized in diagnosis and treatment for cancer’s patients. Their Oncogenetic unit quickly understood the power of SOPHiA AI: “Working with SOPHiA GENETICS was a logical next step for us to streamline our clinical genomic analysis processes. While our demand in Next-Generation Sequencing (NGS) both research and diagnostic continue to grow, we needed a centralized and powerful technology to analyze quickly and precisely the large amount of data. The high analytical performance, its interpretation capabilities, and the support provided has been key in our decision to adopt SOPHiA AI and join the world’s largest community in Data-Driven Medicine.” Dra. Edenir Palmero – Manager Oncogenetics Lab
In addition of SOPHiA’s rapid adoption in the Brazilian healthcare space, SOPHiA GENETICS is proud to announce that the company has recently been selected to be part of the 2018 TechEmerge Project organized by the IFC (World Bank Group) in Brazil. Participants have been given the opportunity to meet with selected healthcare providers to build innovative pilot projects in order to further accelerate the adoption of their technologies.
“Since inception, our vision has been to develop innovative technological solutions to help patients, equally wherever they live. SOPHiA acts as a real disruptor by breaking down the information silos in healthcare, meaning that the information from a patient in Paris can for instance help better diagnose and treat a patient in Rio de Janeiro.” – Dr. Jurgi Camblong, CEO and Co-Founder of SOPHiA GENETICS
